Formulary Watch |

All News - Page 6

Evernorth is “Foundational” to Cigna’s Business
Evernorth is “Foundational” to Cigna’s Business
Evernorth is “Foundational” to Cigna’s Business
February 2, 2024
The bulk of Cigna’s $195.3 billion 2023 revenue comes from Evernorth. And Cigna is positioning itself to grow Evernorth even more.
 stas_malyarevsky-stock.adobe.com
Medicare Drug Price Negotiation Begins Today
Medicare Drug Price Negotiation Begins Today
February 1, 2024
New research finds that in 2022, U.S. prices across all drugs were almost three times higher than in other countries.
Biogen to Stop Selling Alzheimer’s Drug Aduhelm
Biogen to Stop Selling Alzheimer’s Drug Aduhelm
Biogen to Stop Selling Alzheimer’s Drug Aduhelm
January 31, 2024
Biogen will focus its resources on Leqembi and research of other treatments for Alzheimer’s disease.
AIGen-stock.adobe.com
FDA Warns About Malignancies from CAR-T Therapies
FDA Warns About Malignancies from CAR-T Therapies
January 26, 2024
The FDA orders new warnings for CAR-T cell therapies due to reports of T-cell malignancies, including fatal cases, applying to BCMA- and CD19-directed genetically modified autologous T-cell immunotherapies.
Tyson Foods Selects Rightway as its PBM over CVS Caremark
Tyson Foods Selects Rightway as its PBM over CVS Caremark
Tyson Foods Selects Rightway as its PBM over CVS Caremark
January 25, 2024
CVS Caremark will continue to manage specialty drug benefits for Tyson Foods.
Drug Price Transparency Takes a Coalition
Drug Price Transparency Takes a Coalition
Drug Price Transparency Takes a Coalition
January 25, 2024
Joseph M. Shields talks about the formation of Transparency-Rx and its goals of achieving PBM reform that focuses on “corrective steps to address the misalignment in the marketplace to ensure that there’s competition and choice.”
anatolir-stock.adobe.com
HHS Reminds Plans to Provide Coverage for Contraception
HHS Reminds Plans to Provide Coverage for Contraception
January 24, 2024
Coverage of contraceptives and contraceptive care without cost-sharing is required under the Affordable Care Act.
10 State Medicaid Programs Include Pheburane for Urea Cycle Disorders
10 State Medicaid Programs Include Pheburane for Urea Cycle Disorders
10 State Medicaid Programs Include Pheburane for Urea Cycle Disorders
January 23, 2024
Current treatments for urea cycle disorders, which causes ammonia to build up in the blood, have a bitter taste and smell. Pheburane was developed with a special coating that masks the taste of sodium phenylbutyrate. It has a list price of $4,375 per bottle.
Will Patients Benefit from Drug Price Negotiations?
Will Patients Benefit from Drug Price Negotiations?
Will Patients Benefit from Drug Price Negotiations?
January 22, 2024
Peter Rubin of No Patient Left Behind worries that patients may not see benefits, either in lowered costs or continued investment in new therapies, from drug price negotiations required under the Inflation Reduction Act.
weyo-stock.adobe.com
Important Vaccines Approved in 2023, But Vaccine Hesitancy Persists
Important Vaccines Approved in 2023, But Vaccine Hesitancy Persists
January 19, 2024
Last year saw the approval of several firsts, including the first vaccines to prevent respiratory syncytial virus in older adults and infants and a first vaccine to prevent the mosquito-borne virus chikungunya.
Justice Department Drops Appeal in Copay Assistance Case
Justice Department Drops Appeal in Copay Assistance Case
Justice Department Drops Appeal in Copay Assistance Case
January 18, 2024
A 2020 rule stands in which copay assistance from pharmaceutical companies counts toward deductibles for brand name drugs without a generic competition.
agenturfotografin-stock.adobe.com
Biosimilars to Lead to $192 Billion Loss for Originators by 2028
Biosimilars to Lead to $192 Billion Loss for Originators by 2028
January 18, 2024
IQVIA’s most recent Global Use of Medicines report projected that market introductions of new biosimilar and generic drugs will increase projected losses for originator products from $111 billion to $192 billion over the next five years.
Vitalii Vodolazskyi-stock.adobe.com
Study: Health Plan Design Influences Biosimilar Adoption
Study: Health Plan Design Influences Biosimilar Adoption
January 16, 2024
Less flexible plans, such as health maintenance organizations, are more likely to use biosimilar therapies than more flexible plans.
Optum Rx Revenue Grew 16% in 2023
Optum Rx Revenue Grew 16% in 2023
Optum Rx Revenue Grew 16% in 2023
January 12, 2024
UnitedHealth Group executives attribute the increase of revenue at Optum Rx to the addition of new clients, expanded relationships with existing clients, and advancements in services.
© 2024 MJH Life Sciences

All rights reserved.